Legend Biotech has been granted a patent for constructs containing a single-domain antibody that targets TIGIT. The construct includes specific amino acid sequences for CDR1, CDR2, and CDR3. This innovation opens new possibilities for therapeutic applications targeting TIGIT. GlobalData’s report on Legend Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Legend Biotech Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Legend Biotech, was a key innovation area identified from patents. Legend Biotech's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Constructs with single-domain antibody recognizing tigit

Source: United States Patent and Trademark Office (USPTO). Credit: Legend Biotech Corp

A recently granted patent (Publication Number: US11905327B2) discloses an anti-TIGIT construct designed to target TIGIT, a protein involved in immune responses. The construct comprises a single-domain antibody (sdAb) moiety with specific amino acid sequences in its CDR1, CDR2, and CDR3 regions. Additionally, the sdAb moiety can be camelid, chimeric, human, partially humanized, or fully humanized, providing versatility in its application.

Furthermore, the patent describes the anti-TIGIT construct as an sdAb-Fc fusion protein, where the Fc fragment can be a human IgG1 (hIgG1) Fc, effectorless hIgG1 Fc, or hIgG4 Fc. The construct can also include a second antibody moiety recognizing a different epitope, connected by a peptide linker. Methods for producing the anti-TIGIT construct and treating TIGIT-related diseases in individuals are also outlined in the patent, offering potential therapeutic applications in the field of immunotherapy.

To know more about GlobalData’s detailed insights on Legend Biotech, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies